Proteomics International seeks FDA approval for PromarkerD

Pre-submission package for diabetic kidney disease (DKD) test lodged with the US Food and Drug Administration (FDA). Proteomics International expected to meet with the FDA to progress clearance within 10 weeks.

FDA pre-submission follows CE Mark regulatory approval for PromarkerD in Europe.

Media Release